We developed a novel blood glucose control system, using a model predictive method, to achieve optimal control of the blood glucose level in severely diabetic or pancreatectomized patients. This system is designed to predict glucose level changes in advance, considering delayed response time and the administered doses of insulin. This method is also designed to calculate the most appropriate insulin infusion rate by considering differences in individual response to insulin. In this study, we compared our system with a conventional proportional and differential controller (PD controller) to determine whether the new system could regulate the glucose level efficiently in pancreatectomized dogs. The model predictive control method resulted in a significant reduction of mean insulin infusion rate compared with the conventional PD controller (0.71 mU/kg per min vs. 1.81 mU/kg per min, p ‫؍‬ 0.0005), when the glucose level in both methods reached the planned target level (100 mg/dl). The new system also tended to have a reduced mean glucose infusion rate for compensating for overshooting of the glucose level compared with the PD controller (0.7 mg/kg per min vs. 1.1 mg/kg per min, p ‫؍‬ 0.16). These results indicate that the new system should be a useful tool for regulating the glucose level in severely diabetic patients. ASAIO Journal 2000; 46:657-662.
Diabetic patients lack positive feedback regulation between blood sugar concentration and insulin secretion. Considerable effort has been directed toward developing closed-loop insulin delivery systems, which efficiently connect sugar profile and insulin release. Some investigators have introduced an artificial pancreas, STG-22 (Nikkiso Co., Tokyo, Japan), for clinical treatment of such patients. This apparatus is designed to automatically maintain proper blood glucose levels in severely diabetic patients. The control method used in the STG-22 apparatus is a conventional proportional and differential controller (PD controller) based on an algorithm that simulates the characteristics of physiologic insulin secretion by the healthy human pancreas. [1] [2] [3] However, clinical application of the STG-22 apparatus sometimes resulted in unsatisfactory outcomes because the blood glucose level did not reach the target level or overshot the target level. Moreover, the total doses of insulin infused by the STG-22 apparatus seemed to be high.
To solve these problems, the model predictive control method was introduced as the blood glucose regulatory system, 4 -6 to achieve optimal control of blood glucose levels. This model predictive method is widely applied in industrial chemical plants to enable precise regulation of inefficient systems. The model predictive method determines the manipulated input based on the impulse response model, or the step response model that describes the characteristics of the plant, and has few tuning parameters that are adjusted according to actual circumstances.
In this study, we applied the model predictive method to develop a closed-loop insulin infusion system to obtain optimal control of blood glucose levels. We also compared the performance characteristics using fixed parameters between the model predictive control method and the conventional PD controller of the STG-22 in an animal model using pancreatectomized dogs.
Materials and Methods

Model Predictive Control Method
The basic concept of the model predictive control method is illustrated in Figure 1 . First, the blood glucose level y(t) at time t (current point) is measured, and a reference trajectory yR(t ϩ i) (i ϭ 1,2,. . .) is determined so as to converge with the planned target level, R. The insulin infusion rate u(t ϩ i) (i ϭ 0,1,2,. . .M-1) in [t,t ϩ M] (control horizon) is then determined so that the predicted blood glucose level yP(t ϩ i) (i ϭ 1,2. . .) based on the model of the response of blood glucose level to intravenous insulin infusion may be closest to the reference trajectory in [t ϩ L, t ϩ LϩP] (coincidence horizon). Insulin is continuously infused at the calculated rate u(t) until the next sampling point t ϩ 1. The same procedure is repeated considering time t ϩ 1 as the current point. Next, we determined a more concrete equation for insulin infusion rate calculation. Suppose that the model of the response of blood glucose level to intravenous insulin infusion is given by
The predicted blood glucose level can then be calculated by yP͑t ϩ j͒ ϭ y͑t͒ ϩ ͕ yM͑t ϩ j͒ Ϫ yM͑t͖͒.
(
Under the assumption that the insulin infusion rate after time t ϩ M is constant, the insulin infusion rate u(t ϩ i)(i ϭ 0,1,2, . . .M-1) in [t,t ϩ M] is determined so that the squared error between the predicted blood glucose level and the reference trajectory
may be minimized. In our system, the model of the response of blood glucose level to intravenous insulin infusion is given as a "first order delay plus dead time" system:
Here, T0 is the sampling period, K is a gain, T is a timeconstant, and Td is the number of steps in a dead-time TL (Td ϭ T0TL). The reference trajectory is given by
where s is the time after which the step response of blood glucose level to intravenous insulin infusion can be regarded as a constant, i.e., ⌬u(t Ϫ i) ϭ 0 (izs). From equations 2-5, the insulin infusion rate can be obtained by
Here, A, B, and C are vectors determined from the model, the reference trajectory, and so on. As for the detailed calculation method of A, B, and C. 4 -6 Blood Glucose Control System
The blood glucose control system consists of a sensor, a controller, and an effector. The sensor part of the STG-22 apparatus is used in our system for continuous monitoring of the blood glucose level. The sensor has a glucose oxidase based enzyme electrode that detects a current change at the initial voltage, reflecting the oxidation of glucose by enzyme. The STG-22 apparatus monitors the venous blood glucose level continuously, and transmits the data to a personal computer every 10 seconds. The personal computer, programmed using C language, acts to determine the insulin infusion rate based on the model predictive method. Instructions given by the computer are transmitted to an insulin microinfusion pump (IVAC 770, IVAC Corp., San Diego, CA) every 2 minutes, to lower the blood glucose level. A short-acting solution of human insulin (Humulin R, U-40; Eli Lilly Co., Indianapolis, IN) is used for this evaluation.
When the blood glucose level falls below the target level, the system determines the glucose infusion rate using a proportional method that acts to return the blood glucose to the target level, as well as to prevent hypoglycemia. The computer gives instructions for the appropriate glucose infusion rate to a glucose infusion pump (IVAC 560, IVAC Corp.) every 10 seconds. The glucose pump infuses a 10% glucose solution to attain the target level (Figure 2) .
Experimental Design
Eleven adult mongrel dogs weighing approximately 10 to 18 kg underwent total or subtotal pancreatectomy to provide a model of diabetes mellitus. The artificially pancreatectomized dogs received insulin injections subcutaneously to maintain the fasting glucose level below 250 mg/dl for more than 3 weeks before the study. After the fasting blood glucose levels were confirmed to be higher than 200 mg/dl, insulin administration was stopped 24 hours before the study. All dogs lost approximately 2 to 4 kg of body weight after the pancreatectomy. Each dog fasted overnight and was put under general anesthesia using an intramuscular injection of 10 mg/kg body weight of ketamine hydrochloride followed by intravenous injection of 25 mg/kg body weight of pentobarbital sodium. Anesthesia was maintained after intubation with inhalation of nitrous oxide, oxygen, and halothane under controlled respiration. Blood samples were withdrawn continuously from the external jugular vein by means of an indwelling double-lumen catheter, to monitor the blood glucose level with the STG-22 apparatus. The continuous withdrawal of whole blood at the rate of 2 ml/h is adequate to provide sufficient blood glucose sensitivity. A foreleg vein was used for the continuous infusion of Ringer's lactate solution, insulin that was diluted in normal saline to 100 mU/ml, and 10% glucose solution (Figure 2) .
Before the blood glucose regulation experiment, dehydration of the pancreatectomized dogs was corrected by an infusion of 200 ml of Ringer's lactate without glucose, followed by continuous infusion of Ringer's lactate without glucose at 3 ml/kg per h to compensate for natural water loss. Blood glucose control using either the model predictive control method or the conventional PD controller was started when the blood glucose level became stable. The target level for blood glucose was set at 100 mg/dl in both methods. The parameters used for the model predictive control method were those determined to be appropriate in our preliminary studies. The model of controlled object using MPC is based on a "first order delay plus dead time" system where the gain K is 700 mg kg min/dl per mU, the time constant T is 300 min, and the dead time T L is 20 min. The beginning of the coincidence horizon L and the control horizon M are set at T d ϩ 1 (T d : dead time in discrete time) and 1, respectively. The prediction horizon P and a parameter to decide the reference trajectory a are decided by a simulation to regulate the blood glucose level in a pancreatectomized dog model. Consequently, P and a are set at 90 and 0.97, respectively.
For the conventional PD controller, the initial set of parameters recommended by the manufacturer was used (IA, IB, IC, ID, GA, GB, GC, and GD were 2, 35, 0.225, 100, 0.3, 0.3 0, and 100, respectively). The parameters were fixed throughout the evaluation with both methods.
The mean insulin infusion rate is calculated in the interval between the initial point and the point where the target level is reached, and expressed as mU/kg per min, and the mean glucose infusion rate is calculated from the amount of glucose infusion required to prevent overshooting during the 60 min period after the target level is reached. Mean glucose infusion rate is expected to reflect the degree of excessive insulin infusion in both methods, while the blood glucose is reaching the target level. All experiments were performed according to the institutional guidelines of Kyoto University for the care and use of laboratory animals.
Statistical Analysis
Statistical analysis was carried out with an unpaired Student's t-test. The significance level was set at p Ͻ 0.05.
Results
Typical Cases of the Model Predictive Control Method and the Conventional PD Controller
Typical cases of blood glucose control using the model predictive control method and the conventional PD controller are illustrated in Figures 3 and 4 . With the PD controller in dog No. 3, when the initial blood glucose level was 370 mg/dl, a relatively high insulin infusion rate (5.6 mU/kg per min) was observed. This high rate was determined by the proportional part of the conventional PD controller. With the fall in glucose level, the proportional part as well as the differential part of the conventional PD controller worked appropriately and it took 231 min to reach the target level (100 mg/dl), at a mean insulin infusion rate was 2.24 mU/kg per min. When the glucose level fell below the target level, compensatory glucose infusion was started, and the mean glucose infusion rate was 1.0 mg/kg per min (Figure 3, Table 1 ).
Using the same dog (No. 3) and an initial blood glucose level of 378 mg/dl, a low insulin infusion rate (1.1 mU/kg per min) was observed with the model predictive control method. With the fall in glucose level, the model predictive control method started to regulate blood glucose appropriately and it took 244 min to reach the target level (100 mg/dl). A blood glucose curve similar to that seen with the conventional PD controller was obtained with the model predictive control method. The mean insulin infusion rate was 0.73 mU/kg per min, and the mean compensatory glucose infusion rate was 1.0 mg/kg per min (Figure 4, Table 1 ). Although the amount of glucose infusion was almost the same in the two methods, the mean insulin infusion rate was lower with the model predictive control method than with the conventional PD controller (Figures 3 and 4) .
In another dog (No.1) with a similar initial blood glucose level (409 mg/dl), the model predictive control method regulated the blood glucose to the target level within 213 min. The initial insulin infusion rate was 1.8 mU/kg per min and the mean insulin infusion rate was 1.09 mU/kg per min. The mean compensatory glucose infusion rate was 1.2 mg/kg per min (data are not shown). These results suggest that the model predictive control method could work properly irrespective of differences in individual response to insulin. The abrupt drops in blood glucose level that are shown in the graphs were artifacts caused by transient occlusion or flushing of the blood sampling line.
Comparison of the Model Predictive Control Method and the Conventional PD Controller for Blood Glucose Control
By using the model predictive control method, the blood glucose level reached the target level within approximately 6 hours in six of seven dogs. In the other dog, the blood glucose level had not reached the target level within 8 hours. By using the conventional PD controller, the blood glucose level reached the target level within a similar period in seven of nine dogs. In the other two dogs, the blood glucose level did not reach the target level within 8 hours ( Table 1) . The time course of the blood glucose control in seven pancreatomized dogs using the model predictive control method are illustrated in Figure 5 .
The model predictive control method resulted in a significant reduction in mean insulin infusion rate compared with the conventional PD controller (0.71 mU/kg per min vs. 1.81 mU/kg per min, p ϭ 0.0005); mean glucose infusion rate also tended to be lower with the model predictive control method than with the conventional PD controller (0.7 mg/kg per min vs. 1.1 mg/kg per min, p ϭ 0.16) ( Table 1 ).
Discussion
The development of a closed-loop insulin infusion system is promising, especially for patients with severe diabetes mellitus. Although the conventional PD controller for controlling blood glucose is already available, 1-3,7-9 this system has the disadvantage of not reaching the target level or overshooting the planned level unless appropriate parameters are used. Moreover, even if the blood glucose level is kept at the target level without disturbance, the system cannot always maintain the blood glucose level at the target level against disturbance. We previously developed a computer controlled blood pressure autoregulating system and used it during surgery. 10 -12 That system is safe, stable, and effective in reducing the blood loss during major surgery that otherwise might cause substantial blood loss.
In this study, we introduced the model predictive control method to establish an efficient control system for blood glucose regulation. This system is designed to predict blood glucose changes in advance, considering the delayed response of the glucose level to insulin, as well as the administration dose of insulin. Because this controller has the ability to track step references, the blood glucose level can always reach and be kept at the target level. Our present study clearly showed that this new system could control the blood glucose level more efficiently than the current PD controller. When the appropriate parameters were used for both of the controllers, the model predictive control method had a significantly reduced insulin infusion rate compared with the conventional PD controller ( Table 1 ). The new system also tends to have a reduced mean glucose rate for compensating overshooting of the blood glucose level. Application of the model predictive controller resulted in no excessive infusion of insulin at the beginning of control, and the amount of glucose infusion necessary for the return to the target level was kept to a minimum. Therefore, this controller calculates the most appropriate infusion rate by considering the individual response to infused insulin. Consequently, an almost ideal result with minimal total insulin infusion and minimal glucose compensation was obtained.
This finding is clinically very important, because recent research on diabetes revealed that insulin resistance and subsequent chronic hyperinsulinemia is closely related to the development of obesity, hyperlipidemia, hypertension, and worsening diabetes. There is a consensus that in controlling blood glucose, the smaller the amount of insulin needed, the better the outcome of the disease. 13, 14 There have been prior reports of simulations using linear and nonlinear models for blood glucose regulation by insulin, but none of the models were used in clinical application. [15] [16] [17] Parker et al. also tried to control blood glucose with model predictive control methods. 18 However, they used a model with parameters determined by preliminary identification in each patient. Our system uses a linear model predictive controller using a general model with fixed parameters. Furthermore, we have chosen a simple model "first order delay plus dead time" system to cope with individual differences. Therefore, our system can be applied more widely as a blood glucose control method.
However, there are several problems to be overcome before the system can be used in patients. The first problem is to find more robust parameters for universal usage of this system. In fact, we have found in animal experiments that there exist a wide variety of differences in the insulin response among individuals. Consequently, it is sometimes difficult to reach the target blood glucose using predetermined parameters, even with the model predictive method. We are currently trying to improve the system by adding individual identifying functions. The second issue is the regulation within another environment, such as continuous addition of glucose. Our current study exclusively focused on regulation without an external glucose challenge. However, it is anticipated that a more sophisticated system will be needed for the clinical setting. Experiments to solve this problem are now under way in our laboratory.
In addition to the disadvantages of the conventional PD controller, the STG-22 apparatus is so big that it can be used at bedside only. Moreover, the sensitivity of the glucose sensor decreases with time and blood glucose monitoring becomes unstable. An easy, painless, and noninvasive blood glucose measurement without the need for a blood sample would be ideal; however, the extraction of quantitative analytic information on metabolites using transcutaneous in vivo spectroscopy still poses many practical problems. 19 -24 These problems can only be solved by further interdisciplinary, basic research within the challenging field of skin spectroscopy. Diabetic patients still dream of a noninvasive or, at least, minimally invasive method that allows reliable glucose regulation, avoiding the painful conventional method. Our novel regulation system, together with advances in glucose monitoring, may ease the daily burden of glucose regulation in patients with diabetes mellitus.
